Molina Healthcare of New Mexico, Inc. ("Molina")
COVID-19 Member Cost-Share
September 9, 2020

****IMPORTANT****

Molina is reminding all contracted providers that Molina members should not be charged for COVID-19 testing or treatment.

WHAT MOLINA IS DOING TO HELP ITS MEMBERS:

Molina will waive co-pays and cost share for the diagnostic laboratory test for COVID-19. (If the outbreak continues please monitor our provider notifications for potential extension of this policy). This policy will cover the test kit for patients who meet CDC guidelines for testing, which can be done in any approved laboratory location. Molina will waive the member costs associated with this diagnostic testing for COVID-19 at any authorized location for all Medicare, Marketplace, and Medicaid lines of business. No Prior Authorization is needed for this testing.

Molina will offer zero co-pay and cost share for participating (PAR) telemedicine visits (where these are a covered benefit) - for any diagnosis. (If the outbreak continues please monitor our provider notifications for potential extension of this policy). Molina members should use telemedicine as their first line of defense in order to limit potential exposure in physician offices. Cost sharing will be waived for all video visits by in-network providers delivering synchronous virtual care (live video-conferencing) for those plans that cover this type of service.

Molina Healthcare of NM Marketplace members may contact TELADOC® at 1-800-TELADOC (835-2362) or visit teladoc.com/molinamarketplace.

Molina will waive co-pays and cost share for office visits, urgent care visits, and ED visits where the diagnosis rendered is specifically related to COVID-19. (If the outbreak continues please monitor our provider notifications for potential extension of this policy). Visits for other symptoms or diagnoses will not have co-pay or cost share removed. This includes not removing cost share for other laboratory testing (besides COVID-19 testing), x-rays, or other add-on testing.

Molina will relax refill timing on all prescriptions. (If the outbreak continues please monitor our provider notifications for potential extension of this policy). Refill timing will be relaxed to allow a one-time refill of covered prescription medications prior to expiration of the normal refill waiting period, taking into due consideration risks associated with certain drug classes.

Molina will allow 90-day prescription volumes. This covers prescriptions and refills performed at any in-network.

Molina Nurse Advise Line will continue to be available 24 hours a day, 7 days a week.

Molina Healthcare of New Mexico Nurse Advise Line

(888) 275-8750 (English)

(866) 648-3537 (Spanish)

TTY: 711

Epidemiologic factors that may help guide decisions on whether to test include: any persons (including healthcare workers) who have had close contact with a laboratory-confirmed COVID-19 patient within 14 days of symptom onset, or a history of travel from affected geographic areas within 14 days of symptom onset. When there is a suspected case of COVID-19, clinicians should immediately notify their state or local health department and implement infection control practices.

As availability of diagnostic testing for COVID-19 increases, clinicians will be able to access laboratory tests for diagnosing COVID-19 through clinical laboratories performing tests authorized by FDA under an Emergency Use Authorization (EUA). Clinicians will also be able to access laboratory testing through public health laboratories in their jurisdictions. ***Clinicians are required to include all applicable diagnosis codes on laboratory requisition requests when ordering laboratory services.***

What billing codes are related to COVID-19?

CPT	**Description HCPCS**
U0001	This code is used specifically for CDC testing laboratories
U0002	This code is used for non–CDC testing laboratories
0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed
87635	Infectious agent detection by nucleic acid (DNA or RNA); sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique *(Effective March 13, 2020)*
86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source)

ICD-10	Description
U07.1	COVID-19
B97.29	Other coronavirus as the cause of diseases classified elsewhere ***ICD-10 Diagnosis Code B97.29 is required on all applicable claims in order for member cost share to be waived. Claims submitted without B97.29 will be processed to apply member cost share.***
Z03.818	Encounter for observation for suspected exposure to other biological agents - ruled out
Z20.828	Contact with and (suspected) exposure to other viral communicable diseases

Resource References

CDC: ICD-10-CM Official Coding Guidelines – Supplement. Coding encounters related to COVID-19 Coronavirus Outbreak. Effective: February 20, 2020.

AMA: CPT® Category I Pathology and Laboratory Code for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) Updated March 13, 2020